 |
|
|
| |
Efficacy and Safety Results from a Randomized, Double-Blind, Active-Controlled Trial of Elvitegravir (Once-Daily) vs. Raltegravir (Twice-Daily) in Treatment-Experienced HIV-Infected Patients: Long Term 96-Week Data
|
| |
| |
Reported by Jules Levin
XIX International AIDS Conference
July 24, 2012
Richard Elion1, Jean-Michel Molina2, Jose-Ramon Arribas-Lopez3,
David A Cooper4, Franco Maggiolo5, Edmund Wilkins6, Brian Conway7,
Ya-Pei Liu8, Lijie Zhong8, Nicolas Margot8, Javier Szwarcberg8, Martin S Rhee8, Andrew K Cheng8
1Whitman-Walker Health, Washington DC, United States, 2Hopital Saint Louis, Service des Maladies infectieuses, Paris, France, 3Hospital Universitario La Paz, Servicio de Medicina Interna, Unidad VIH, Madrid, Spain, 4Kirby Institute, University of New South Wales, Sydney, Australia, 5Ospedali Riuniti di Bergamo, Bergamo, Italy, 6North Manchester General Hospital, Manchester, United Kingdom, 7Vancouver ID Research & Care Centre, Vancouver, Canada, 8Gilead Sciences, Foster City, United States
|
| |
|
|
|
|
|
